Intract

EQS-News: tokentus investment AG invests USD 100,000 in Intract Tech PTE LTD, a Web3 Learn-&-Earn Platform

Retrieved on: 
Tuesday, November 7, 2023
Alchemy, Decentralized finance, ISIN, Polygon, Non-fungible token, Alpha wave, Blockchain, Investment, WKN, Decentralized application, Intract, USD, NFT, AG, Bank, Cryptocurrency, Coinbase, Binance

tokentus investment AG invests USD 100,000 in Intract Tech PTE LTD, a Web3 Learn-&-Earn Platform

Key Points: 
  • tokentus investment AG invests USD 100,000 in Intract Tech PTE LTD, a Web3 Learn-&-Earn Platform
    The issuer is solely responsible for the content of this announcement.
  • tokentus investment AG invests USD 100,000 in Intract Tech PTE LTD, a Web3 Learn-&-Earn Platform
    Intract supports Web3 communities to grow their DeFi, NFT, GameFi or DApp users
    Frankfurt am Main, 01.
  • November 2023 - Frankfurt-based tokentus investment AG ("tokentus", ISIN: DE000A3CN9R8; WKN: A3CN9R; symbol: 14D) is investing USD 100,000 in the seed investment round of Intract Tech PTE LTD (known as Intract), a Singapore-based corporation, founded in 2022.
  • Based on their product description Intract helps Web3 users connect with and explore the communities of their choice through its interactive platform.

Oral Drug Delivery Global Market Report 2022: Featuring Pfizer, AstraZeneca, Alpex Pharma, Globela, Lupin, AdhexPharma & More - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Health, Pharmaceutical, Prevalence, Ageing, Nanotechnology, World Health Organization, GlobalData, Moyamoya disease, Conditional sentence, SWK, Intract, Patent, Research, Acquisition, American Cancer Society, Endometrial cancer, COPD, Mortality, Type 2 diabetes, Diabetes, Growth, Administration, Media, Stroke, Smoking, History, Chronic obstructive pulmonary disease, Pharmaceutical industry, Dietary supplement, Public health

The "Oral Drug Delivery Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Drug Delivery Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Oral drug delivery systems are expected to become more popular as the prevalence of chronic diseases rises around the world.
  • During the projected period, North America is anticipated to dominate the oral drug delivery market.
  • For example, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical firm researching oral drug delivery systems, got a US patent in March 2019.

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

Retrieved on: 
Monday, September 27, 2021
Research, Technology, Other Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Biotechnology, News, Compliance, IBD, Inflammation, Degenerative disease, Therapy, Adalimumab, Colon, Cancer, Patient, Engineering, Marketing, CEO, Pharmacy, WeChat, Mab, Autoimmunity, Intract, GI, Extrapyramidal system, Technology, Conditional sentence, Forward-looking statement, Safety, Enzyme, Pharma, Intellectual property, Neutralizing antibody, Protein, Pharmaceutical industry, Vaccine, Bio-Thera Solutions, Ltd., Intract Pharma, BIO-THERA SOLUTIONS, LTD., INTRACT PHARMA

Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.

Key Points: 
  • Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.
  • Under the terms of the agreement, Intract has granted Bio-Thera a worldwide license to Intracts oral biologics drug delivery platform for a single undisclosed mAb product.
  • Intract will receive an undisclosed upfront payment, with potential development and commercial milestone payments along with royalties on product sales.
  • Intracts oral biologics delivery platform includes Soteria a technology which protects proteins such as mAbs from degradation in the intestinal lumen.